CMA “ignored” evidence in excessive pricing case, Pfizer says

Emily Craig

27 November 2019

CMA “ignored” evidence in excessive pricing case, Pfizer says

Credit: iStock/Fahroni

The UK’s Competition and Markets Authority “ignored” evidence in its decision that two drug companies’ prices were excessive, their defence counsel have argued.